Literature DB >> 16008128

Senna and the formation of aberrant crypt foci and tumors in rats treated with azoxymethane.

F Borrelli1, R Capasso, G Aviello, G Di Carlo, A A Izzo, N Mascolo, F Capasso.   

Abstract

Chronic use of anthraquinone laxatives has been blamed for the induction of habituation and the development of colonic cancer, but there are no definitive studies which have demonstrated this. To evaluate the carcinogenic potential of anthraquinones, the effect of long-term senna pod extract (SE) treatment on either healthy rats or rats treated with an initiating tumor agent (azoxymethane--AOM) has been studied. SE (30 and 60mg/kg), administered for 110 weeks, did not induce the development of aberrant crypt foci (ACF) and tumors in healthy rats. The development of ACF and tumors in rats treated with AOM were significantly reduced by SE (30 and 60 mg/kg). These results suggest that a chronic SE use does not predispose to colon cancer. By contrast, SE might exert an anti-tumoral activity on rat colon carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16008128     DOI: 10.1016/j.phymed.2003.10.008

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  3 in total

1.  Toxicology and carcinogenesis study of senna in C3B6.129F1-Trp53 tm1Brd N12 haploinsufficient mice.

Authors:  Inok Surh; Amy Brix; John E French; Bradley J Collins; J Michael Sanders; Molly Vallant; June K Dunnick
Journal:  Toxicol Pathol       Date:  2012-11-02       Impact factor: 1.902

2.  Is senna laxative use associated to cathartic colon, genotoxicity, or carcinogenicity?

Authors:  M A Morales; D Hernández; S Bustamante; I Bachiller; A Rojas
Journal:  J Toxicol       Date:  2009-09-10

3.  Anti-proliferative effect of rhein, an anthraquinone isolated from Cassia species, on Caco-2 human adenocarcinoma cells.

Authors:  Gabriella Aviello; Ian Rowland; Christopher I Gill; Angela Maria Acquaviva; Francesco Capasso; Mark McCann; Raffaele Capasso; Angelo A Izzo; Francesca Borrelli
Journal:  J Cell Mol Med       Date:  2009-06-16       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.